Dashboard
Manage Tickers

CLDX Celldex Therapeutics, Inc.

Nasdaq celldex.com


$ 24.98 $ -0.66 (-2.58 %)    

Wednesday, 19-Nov-2025 15:51:14 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 610.54 $ 0.00 (0 %)
DIA $ 464.67 $ 0.00 (0 %)
SPY $ 671.16 $ 0.00 (0 %)
TLT $ 88.82 $ 0.00 (0 %)
GLD $ 376.00 $ 0.00 (0 %)
$ 24.92
$ 25.35
$ 23.70 x 20
$ 26.57 x 5
-- - --
$ 14.40 - $ 29.05
893,460
na
1.66B
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-27-2025 12-31-2024 10-K
5 11-06-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-06-2024 03-31-2024 10-Q
8 02-26-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 02-28-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-06-2021 03-31-2021 10-Q
20 03-29-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-06-2020 03-31-2020 10-Q
24 03-26-2020 12-31-2019 10-K
25 11-12-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 03-07-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-08-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-07-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-08-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 03-14-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-08-2016 06-30-2016 10-Q
39 05-05-2016 03-31-2016 10-Q
40 02-23-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

barclays-maintains-underweight-on-celldex-therapeutics-lowers-price-target-to-21
Barclays Maintains Underweight on Celldex ...
11/11/2025 15:03:57

Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Underweight and lowers the price target fr...

celldex-therapeutics-q3-eps-101-misses-091-estimate
Celldex Therapeutics Q3 EPS $(1.01) Misses...
11/10/2025 21:46:21

Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate o...

tech-rallies-palantir-jumps-6-as-shutdown-end-looms-whats-moving-markets-monday
Tech Rallies, Palantir Jumps 6% As Shutdow...
11/10/2025 17:31:17

Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk as...

celldex-releases-new-exploratory-data-from-its-phase-2-study-showing-that-barzolvolimab-improves-urticaria-control-in-patients-with-chronic-spontaneous-urticaria
Celldex Releases New Exploratory Data From...
11/06/2025 13:21:35

Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating barzolvolimab's abilit...

celldex-releases-phase-1-results-for-its-bispecific-antibody-cdx-622-showing-drug-was-well-tolerated-showed-favorable-pharmacokinetics-and-led-to-rapid-sustained-reductions-in-serum-tryptase-confirming-effective-mast-cell-inhibition
Celldex Releases Phase 1 Results For Its B...
10/30/2025 20:14:52

Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that...

mizuho-initiates-coverage-on-celldex-therapeutics-with-outperform-rating-announces-price-target-of-48
Mizuho Initiates Coverage On Celldex Thera...
10/21/2025 12:44:06

Mizuho analyst Joseph Catanzaro initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Outperform rating and announ...

analyst-expectations-for-celldex-therapeuticss-future
Analyst Expectations For Celldex Therapeut...
10/13/2025 20:01:52

barclays-initiates-coverage-on-celldex-therapeutics-with-underweight-rating-announces-price-target-of-25
Barclays Initiates Coverage On Celldex The...
10/13/2025 12:17:38

Barclays analyst Etzer Darout initiates coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Underweight rating and announc...

5-analysts-assess-celldex-therapeutics-what-you-need-to-know
5 Analysts Assess Celldex Therapeutics: Wh...
09/17/2025 14:01:35

canaccord-genuity-maintains-buy-on-celldex-therapeutics-maintains-62-price-target
Canaccord Genuity Maintains Buy on Celldex...
09/17/2025 13:35:57

Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and maintains $62 price target.

celldex-presents-phase-2-data-showing-barzolvolimab-improves-chronic-spontaneous-urticaria-independent-of-baseline-immunoglobulin-e-levels-at-eadv-2025
Celldex Presents Phase 2 Data Showing Barz...
09/17/2025 09:14:33

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
09/08/2025 21:07:27

wells-fargo-maintains-overweight-on-celldex-therapeutics-lowers-price-target-to-38
Wells Fargo Maintains Overweight on Cellde...
08/20/2025 18:47:53

Wells Fargo analyst Derek Archila maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target...

citigroup-maintains-buy-on-celldex-therapeutics-lowers-price-target-to-48
Citigroup Maintains Buy on Celldex Therape...
08/20/2025 16:06:40

Citigroup analyst David Lebowitz maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $5...

celldex-therapeutics-pulls-plug-on-eosinophilic-esophagitis-investigational-drug-as-data-falls-short
Celldex Therapeutics Pulls Plug On Eosinop...
08/20/2025 14:22:16

Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but...

what-analysts-are-saying-about-celldex-therapeutics-stock
What Analysts Are Saying About Celldex The...
08/20/2025 14:01:48

canaccord-genuity-maintains-buy-on-celldex-therapeutics-lowers-price-target-to-62
Canaccord Genuity Maintains Buy on Celldex...
08/20/2025 13:54:53

Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target fr...

la-z-boy-posts-downbeat-q1-results-joins-james-hardie-industries-alcon-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
La-Z-Boy Posts Downbeat Q1 Results, Joins ...
08/20/2025 12:27:54

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/20/2025 12:08:41

why-rocket-pharmaceuticals-shares-are-trading-higher-by-over-15-here-are-20-stocks-moving-premarket
Why Rocket Pharmaceuticals Shares Are Trad...
08/20/2025 11:24:03

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION